Within our Facebook group we had a member state, “I did both medical chemotherapy, surgery, radiation. I also changed my diet to eat barely any processed foods, mostly organically foods, a lot of probiotics, and meats that are organic. Eat nothing out of a can, no soda or alcohol. For lifestyle changes, I also do meditation everyday. Light exercises. Positive affirmations, I changed my way of seeing the world and let go of a lot of stress. And being out in nature everyday.
Idk, those of the things I did. I am in remission, NED from T.N.B.C. I do have a lot of side effects from chemo and radiation that I am trying to heal from. My main message to you would be: I guess is to keep learning take in a lot of information and also do the best you can with the information while listening to your ones body. SO Hopefully, I stay in remission.
Expertscape Ranks World’s Top Doctors and Hospitals in Breast Cancer… it’s always wise to have your breast cancer tested for grade and class and determine if you should have surgery???
PALO ALTO, Calif. – July 1, 2014 – PRLog — As part of its continuing program to highlight expertise and excellence in healthcare, Expertscape recognizes the world’s top institutions and medical specialists in the research and treatment of breast cancer. The most prevalent type of cancer among women, outcomes can vary significantly depending upon the type of cancer, stage and treatment strategy. Patients are likely to benefit from a second opinion from a medical specialist or center with extensive interest in breast cancer treatment and research.
Among the individual experts and institutions demonstrating particular expertise in breast cancer (www.expertscape.com/ex/
Top Experts – Breast Cancer
1. Dr. Gabriel Hortobagyi – MD Anderson Cancer Center
2. Dr. Katherine Pritchard – University of Toronto
3. Dr. Monica Morrow – Memorial Sloan-Kettering Cancer Center
4. Dr. Mitchell Dowsett – Institute of Cancer Research
5. Dr. Eric Winer – Dana Farber Cancer Center
6. Dr. Edith Perez – Mayo Clinic Jacksonville
7. Dr. Daniel Hayes – University of Michigan
8. Dr. Harold Burstein – Dana Farber Cancer Center
9. Dr. Aman Buzdar – MD Anderson Cancer Center
10. Dr. Clifford Hudis – Memorial Sloan-Kettering Cancer Center
Top Institutions – Breast Cancer
1. MD Anderson Cancer Center
2. Memorial Sloan-Kettering Cancer Center
3. Institute of Cancer Research
4. University of Toronto
5. University of Michigan
6. NIH Bethesda
7. Dana Farber Cancer Center
8. University of California San Francisco
9. Johns Hopkins University
10. University of Washington
To view Expertscape’s comprehensive results for breast cancer, covering hundreds of institutions and thousands of specialists worldwide, please visit http://www.expertscape.com/ex/
The Expertscape medical search website helps healthcare consumers quickly and confidently find expert medical advice across over 26,000 medical topics. Expertscape uses its objective algorithms and search methodology to identify the most knowledgeable and experienced doctors and medical institutions by specific medical condition, institution, and geography. To find a comprehensive listing of the top medical experts in any condition, visit www.expertscape.com.
Dr. Edith A. Perez [1], M.D., is a cancer specialist and an internationally known translational researcher who holds positions at both Genentech and Mayo Clinic. She is the Director of the Mayo Clinic Breast Cancer Translational Genomics Program started in 2009 and a Professor of Medicine at Mayo Medical School. In August 2015, Dr. Perez joined Genentech US Medical Affairs (USMA) and also as Vice President and Head of the BioOncology Medical Unit. In her new role, she will also provide leadership for all BioOncology Medical Affairs activities in the United States.
Throughout her career, Dr. Perez has developed a wide range of clinical trials exploring the use of new therapeutic agents for the treatment and prevention of breast cancer. Also In 2005, Dr. Perez, along with her team, revealed the results of the North Central Cancer Treatment Group N9831 Intergroup trial, of which she was the principal investigator. The results showed a considerable decrease in recurrence and also increase in the survival of patients with HER2-positive breast cancer after the inclusion of trastuzumab to adjuvant chemotherapy. Following this result, Dr. Perez progressed into her present work, leading and helping develop basic research studies to evaluate the role of genetic markers in the development and aggressiveness of breast cancer.
Dr. Perez has authored more than 300 peer-reviewed articles and is invited frequently to the lecture at national and international meetings and serves on the editorial boards of multiple academic journals. She has also held positions within Mayo Clinic, the American Association for Cancer Research, the American Society of Clinical Oncology, and the National Cancer Institute.
Dr. Perez earned her medical degree from the University of Puerto Rico School of Medicine in San Juan and completed her residency in internal medicine at the Loma Linda University Medical Center in California. She served as general internist in the Division of National Health Services Corps, Los Angeles, and as a fellow in Hematology/Oncology at Martinez Veterans’ Administration Medical Center at the University of California, Davis School of Medicine. Dr. Perez is board certified in internal medicine, internal medicine – medical oncology and internal medicine – hematology.
Dr. Perez is also a cofounder of the 26.2 with Donna The National Marathon to Finish Breast Cancer , which is also dedicated to breast cancer research and care. It is the only marathon in the U.S. devoted solely to raising funds to end breast cancer.
Also a promising new study from Mayo Clinic, in conjunction with Caris Life Sciences, points to immunotherapy as a possible treatment option for patients with the difficult-to-treat triple negative breast cancer mutation. The study was presented this week at the 50th annual meeting of the American Society of Clinical Oncology in Chicago.
“This study may change our ability to treat triple negative breast cancer patients,” says Barbara Pockaj, M.D., lead investigator of the study and Mayo Clinic surgeon. “We may have signs that these patients can be treated with immunotherapy. We don’t have a lot of options for these patients and this would really expand our options.”
Dr. Barbara A.Pockaj, M.D., a surgical oncologist with a strong clinical and research interest in breast cancer and malignant melanoma. Dr. Pockaj’s research focuses not only on clinical studies but also translational science. She has an extensive clinical database of newly diagnosed breast and melanoma patients that is coupled with a large complementary biobank of breast cancer specimens.
Several areas of clinical research include clinical behavior of triple negative breast cancers, clinical implications of sentinel lymph node biopsy for breast cancer and melanoma, prognostic significance of palpable breast cancer, and ramifications of breast reconstruction.
Dr. Pockaj is the chair of the Breast Cancer Interest Group (BIG), a collaboration between researchers at the Translational Genomics Research Institute (TGen) and Arizona State University (ASU). The collaboration focuses on using the state-of-the-art genomics infrastructure and a high-quality breast cancer tumor biorepository. The focus of the group is to investigate molecular pathways to identify treatment targets for patients with triple negative breast cancer and endocrine-resistant breast cancer.
Focus areas
Dr. Pockaj’s team focuses on:
- Identification of pathways used by triple negative breast cancer for oncogenic growth using clonal analysis of triple negative breast cancer based upon DNA gains or losses. Validation of the abnormal pathway is then evaluated by tissue microarray.
- Characterization of androgen receptor expression in triple negative breast cancer and estrogen-resistant breast cancer. Further evaluation of abnormal gene expression and pathway dysregulation in androgen receptor signaling.
Other research interests:
- Breast cancer — all aspects of the clinical care of breast cancer, including new diagnostic modalities, surgical care and advancement of reconstructive techniques, and clinical outcomes; additionally, translational research involving the molecular phenotypes and their implications, and immunologic aspects (including vaccine therapy)
- Melanoma — all aspects of the clinical care of melanoma
- Single institution and multi-institution clinical trials
- Quality-of-life studies in cancer patients
Significance to patient care
The treatment of breast cancer has changed from treating it as a single disease to considering tailored treatment as a heterogenous groups of cancers with distinctive pathobiology. The molecular classification of major tumor groups is primarily the result of intensive genomics research. This has significant ramifications for treatment potential. This is true for not only breast cancer but also melanoma.
Leveraging our clinical and translational work is the only way to improve treatment for cancer patients in the future.
Professional highlights
- Breast Committee and Quality-of-Life Committee, Alliance for Clinical Trials in Oncology (formerly the North Central Cancer Treatment Group)
- Research Vice Chair, Chair of the Surgery Committee (2003-2011), Surgical Liaison for the Breast and Quality-of-Life Committees — American College of Surgeons Branch of the Alliance for Clinical Trials in Oncology
- Board Member (2008-present), Chair of Program Committee (2006-2007), Publication Committee (2007-present), Research Committee (2008-present) — American Society of Breast Surgeons
- Board Member, Sentinel Lymph Node Working Group (Melanoma), 2005-present
- Neoadjuvant Working Group (2005-2007), Planning Committee for State of the Science Symposium for Preoperative Therapy for Breast Cancer (2006-2007), Chair of Surgical Working Group (2007-2008) — Breast Cancer Intergroup of North America
- Breast Oncology Local Disease (BOLD) Task Force, Breast Cancer Steering Committee, National Cancer Institute, 2009-present
- Member, Society of Surgical Oncology, 1996-present
- Member, American Society of Clinical Oncology, 2005-present.
- pockaj.barbara@mayo.edu
Preview YouTube video The Biology of Triple Negative Breast Cancer – Mark D. Pegram, MD
Preview YouTube video ER/PR+ or HER2+ Breast Cancer: What’s New in Targeted Therapies
